Veracyte, Inc. (VCYT) P/E Ratio History
UndervaluedTrading at 59.2x vs 5Y avg 71.8x · 43th percentile · Below historical baseline · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of September 24, 2026, Veracyte, Inc. (VCYT) trades at a price-to-earnings ratio of 59.2x, with a stock price of $48.54 and trailing twelve-month earnings per share of $1.40.
The current P/E is 18% below its 5-year average of 71.8x. Over the past five years, VCYT's P/E has ranged from a low of 29.9x to a high of 132.0x, placing the current valuation at the 43th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, VCYT trades at a 149% premium to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 164.5x.
Relative to the broader market, VCYT commands a significant premium over the S&P 500 median P/E of 24.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VCYT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VCYT Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
VCYT P/E vs Peers
Diagnostics and Omics Tools peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $648M | 17.6Lowest | 1.59Best | -3% | |
| $1B | 28.5 | 3.82 | +1883%Best | |
| $41B | 50.3 | 11.88 | +171% | |
| $252B | 38.2 | 18.11 | +7% | |
| $17B | 30.5 | - | -25% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
VCYT Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $58.73 | $1.40 | 42.0x | -42% |
| FY2026 Q1 | - | $32.21 | $1.08 | 29.9x | -58% |
| FY2025 Q4 | Dec 31 2025 | $42.10 | $0.82 | 51.6x | -28% |
| FY2025 Q3 | - | $34.33 | $0.38 | 91.4x | +27% |
| FY2025 Q2 | Jun 30 2025 | $27.03 | $0.33 | 83.0x | +16% |
| FY2025 Q1 | Mar 31 2025 | $29.65 | $0.41 | 72.7x | +1% |
| FY2024 Q4 | - | $39.60 | $0.30 | 132.0x | +84% |
Average P/E for displayed period: 71.8x
VCYT Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VCYT — Frequently Asked Questions
Quick answers to the most common questions about buying VCYT stock.
What is VCYT's P/E ratio?
Veracyte, Inc. (VCYT) trailing twelve-month P/E ratio is 59.2x, based on TTM diluted EPS of $1.40. The 5-year average P/E is 71.8x and the historical range spans 29.9x to 132.0x.
Is VCYT stock overvalued or undervalued?
VCYT trades at 59.2x P/E, near its 5-year average of 71.8x. The 43th percentile ranking within the 29.9x–132.0x historical range places valuation within normal bounds.
Is VCYT stock expensive?
VCYT is fairly valued relative to its own history. The current P/E of 59.2x is near the 5-year average of 71.8x (43th percentile of historical range).
What is VCYT's historical P/E range?
Over the past 5 years, VCYT's P/E ratio has ranged from 29.9x to 132.0x, with a median of 72.7x and an average of 71.8x. The current P/E of 59.2x places the stock at the 43th percentile of this range. Full historical data spans 2024–2026.
How does VCYT's P/E compare to the S&P 500?
VCYT trades at 59.2x P/E versus the S&P 500 median of 24.8x. The 139% premium to the market typically reflects higher expected earnings growth or quality.
How does VCYT's valuation compare to Healthcare peers?
Veracyte, Inc. P/E of 59.2x compares to the Healthcare sector median of 23.7x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is VCYT's PEG ratio?
VCYT PEG ratio is N/A, based on a P/E of 59.2x and EPS growth of 164.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is VCYT's earnings yield?
VCYT earnings yield is 1.69%, the inverse of its 59.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.